Recent news on Ibritumomab

Biogen Idec Reports Full Year and Fourth Quarter 2006 Results  -  Feb 15, 2007
WebWire (press release),...including Amevive and our Bio 1 facility, and severance and restructuring charges related to the planned ZEVALIN® (ibritumomab tiuxetan) disposition.

Clinical Practice of Molecular Radiotherapy  -  Jan 31, 2007
Journal of Nuclear Medicine (subscription)Furthermore, the fairly recent Food and Drug Administration approval of 2 radiolabeled monoclonal antibodies, 90 Y-ibritumomab tiuxetan (Zevalin;

Hong Song 1 , Yong Du 2 , George Sgouros 1 , Andrew Prideaux 1 ...  -  Jan 4, 2007
Journal of Nuclear Medicine (subscription)90 Y- and 131 I-anti-CD20 antibodies (ibritumomab tiuxetan and tositumomab, respectively) have been approved for the treatment of refractory low-grade

CHOP Plus Zevalin (REG) Therapy Shows Efficacy In Elderly Patients ...  -  Dec 25, 2006
Medical News Today (press release),Zevalin (90Y Ibritumomab Tiuxetan) treatment was given to patients as a first-line consolidation therapy after patients had received standard chemotherapy.

CHOP Plus Zevalin(R) Therapy is Feasible, Tolerable and Shows ...  -  26 Dec 2006
netPR.pl (komunikaty prasowe),Zevalin (90Y Ibritumomab Tiuxetan) treatment was given to patients as a first-line consolidation therapy after patients had received standard chemotherapy.

Addition of Zevalin to Transplant Chemotherapy Improves Survival ...  -  26 Dec 2006
DG NewsORLANDO, FL -- December 13, 2006 -- The addition of yttrium 90 ibritumomab tiuxetan (Zevalin) to a standard condition regimen for patients undergoing

CHOP Plus Zevalin(R) Therapy is Feasible, Tolerable and Shows ...  -  26 Dec 2006
Earthtimes.orgA Phase II Trial of CHOPchemotherapy followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) forpreviously untreated elderly diffuse large B-cell

Zevalin® Can Safely Be Given With High Dose BEAM with Autologous ...  -  26 Dec 2006
Cancer Consultants (press release),Two studies presented at the 2006 meeting of the American Society of Hematology demonstrated that Zevalin (yttrium 90 ibritumomab tiuxetan) could be

CHOP Plus Zevalin(R) Therapy is Feasible, Tolerable and Shows ...  -  Dec 10, 2006
PR Newswire UK (press release),...elderly patients suffering from the most common type of aggressive NHL, Diffuse Large-B-cell Lymphoma (DLBCL)(1). Zevalin (90Y Ibritumomab Tiuxetan) treatment ...

External Beam Radiation Effective for Recurrences Following ...  Jul 17, 2006
Zevalin is comprised of ibritumomab, a monoclonal antibody that is attached to a radioactive substance called Yttrium 90 (90Y). ... -Cancer Consultants

CHOP-R Followed by Zevalin®/Rituxan® Promising for Previously ...  Jun 21, 2006
Results from a phase II trial reported that CHOP-R followed by Zevalin (90Y ibritumomab tiuxetan) and Rituxan (rituximab) provides high complete response rates ... -Cancer Consultants

Nihon Schering, Daiichi Radioisotope Laboratories to Collaborate ...  Jul 10, 2006
Zevalin (ibritumomab tiuxetan), which was initially approved in the US in 2002, is currently available in 37 countries worldwide. ... -Japan Corporate News

Medicare to Improve Cancer Patient Care  Jun 30, 2006
...approval. CMS will be announcing continuation of current policies for ibritumomab tiuxetan and tositumomab in the near future. They ... -Cancer Consultants



Biogen Idec buys cancer drug firm Conforma  May 4, 2006
Biogen Idec also sells a radiopharmaceutical drug, Zevalin (ibritumomab tiuxetan), and has a number of cancer drugs in development. ... - Pharma Times (subscription)

Survival Improving for Patients with Stage IV Follicular Lymphoma  Apr 17, 2006
...stem cell transplants and the introduction of monoclonal antibody therapy with Rituxan® (rituximab), Bexxar® (iodine 131 tositumomab) and Zevalin (ibritumomab ... - Cancer Consultants

International Orphan Drug Approvals: 1D09C3 and Nexavar  Apr 21, 2006
2 molecule, which differs from that targeted by currently marketed products such as rituximab (Rituxan, made by Biogen Idec), ibritumomab tiuxetan (Zevalin ... - Medscape (subscription)





An infusion of new hope  Mar 31, 2006
The drug works like a smart bomb, delivering radiation directly to tumour cells, uniting the monoclonal antibody search agent "ibritumomab tiuxetan" with the ... - Globe and Mail

Woman's last hope tied up in red tape  Mar 16, 2006
Zevalin works like a smart bomb, delivering radiation directly to tumour cells, uniting the monoclonal antibody search agent "ibritumomab tiuxetan" with the ... - Globe and Mail

TRACON Pharmaceuticals Assembles Industry-Leading Management Team ...  Mar 15, 2006
...of oncology products in development, including the regulatory filings that supported the approval of Rituxan® (rituximab) and Zevalin® (ibritumomab tiuxetan ... - Yahoo! News



... Go to the Article  Feb 13, 2006
The drug Zevalin® (ibritumomab tiuxetan) is being studied in a clinical trial being conducted jointly at MD Anderson and Memorial Sloan-Kettering Cancer ... - CancerWise

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional